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Cellular organelles provide opportunities to relate biological mechanisms to disease. Here we use
affinity proteomics, genetics and cell biology to interrogate cilia: poorly understood organelles, where
defects cause genetic diseases. Two hundred and seventeen tagged human ciliary proteins create a
final landscape of 1,319 proteins, 4,905 interactions and 52 complexes. Reverse tagging, repetition of
purifications and statistical analyses, produce a high-resolution network that reveals organelle-
specific interactions and complexes not apparent in larger studies, and links vesicle transport, the
cytoskeleton, signalling and ubiquitination to ciliary signalling and proteostasis. We observe
sub-complexes in exocyst and intraflagellar transport complexes, which we validate biochemically,
and by probing structurally predicted, disruptive, genetic variants from ciliary disease patients.
The landscape suggests other genetic diseases could be ciliary including 3M syndrome. We show
that 3M genes are involved in ciliogenesis, and that patient fibroblasts lack cilia. Overall, this
organelle-specific targeting strategy shows considerable promise for Systems Medicine.
DOI: 10.1038/ncomms11491 OPEN
1Medical Proteome Center, Institute for Ophthalmic Research, University of Tuebingen, 72074 Tuebingen, Germany. 2Department of Human Genetics and Radboud
Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. 3 Biochemie Zentrum
Heidelberg (BZH), University of Heidelberg, Im Neuenheimer Feld 328, 69120 Heidelberg, Germany. 4 Cell Networks, Bioquant, Ruprecht-Karl University of Heidelberg, Im
Neuenheimer Feld 267, 69120 Heidelberg, Germany. 5 Institute of Systems and Synthetic Biology, Genopole, CNRS, Universite´ d’Evry, 91030 Evry, France. 6Department of
Molecular Epigenetics, Helmholtz Center Munich, Center for Integrated Protein Science, 81377 Munich, Germany. 7 Center for Human Disease Modeling, Duke University,
Durham, North Carolina 27701, USA. 8Department of General Pediatrics, University Children’s Hospital Muenster, 48149 Muenster, Germany. 9German Center for
Neurodegenerative Diseases (DZNE) within the Helmholz Association, Otfried-Mu¨ller Strasse 23, 72076 Tuebingen, Germany. 10Department of Nephrology and
Hypertension, Regenerative Medicine Center, University Medical Center Utrecht, 3584 CT Utrecht, The Netherlands. 11 Department of Otorhinolaryngology and Donders
Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. 12 Telethon Institute of
Genetics and Medicine, TIGEM 80078, Italy. 13Molecular Medicine Unit and Birth Defects Research Centre, UCL Institute of Child Health, London, WC1N 1EH, UK. 14Cell
and Matrix Biology, Inst. of Zoology, Johannes Gutenberg University of Mainz, 55122 Mainz, Germany. 15Cambridge Cell Networks Ltd, St John’s Innovation Centre, Cowley
Road, Cambridge, CB4 0WS, UK. 16Department of Translational Medicine Federico II University, 80131 Naples, Italy. 17Department of Genetics, University Medical Center
Utrecht, 3584 CX Utrecht, The Netherlands. 18 Structural and Computational Biology Unit, European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg,
Germany. 19Centre for Molecular and Biomolecular Informatics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein
Zuid 26-28, 6525 GA Nijmegen, The Netherlands. 20 School of Biomolecular & Biomed Science, Conway Institute, University College Dublin, Dublin 4, Ireland. * These
authors contributed equally to this work. Correspondence and requests for materials should be addressed to M.U. (email: Marius.Ueffing@uni-tuebingen.de) or to R.B.R.
(email: robert.russell@bioquant.uni-heidelberg.de) or to R.R. (email: ronald.roepman@radboudumc.nl).
#The members of UK10K Rare Diseases Group have been listed at the end of the paper.
NATURE COMMUNICATIONS | 7:11491 | DOI: 10.1038/ncomms11491 | www.nature.com/naturecommunications 1
S
tudies relating genetic variation and biomolecular func-
tion1,2 are often illuminating, but can be hampered by the
overall complexity of diseases. Mutations causing the same
diseases are often spread across seemingly disconnected cellular
processes, meaning that a near-complete understanding of the cell
is necessary for a systematic interrogation of disease mechanisms.
Such complexity argues that sub-systems, of reduced complexity,
could be used as models to develop systematic approaches to
study mechanisms of disease. As genome-reduced systems enable
Systems Biology3, isolated systems of reduced complexity, such as
organelles where dysfunction leads to one or more diseases, can
similarly enable Systems Medicine.
Cilia are spatially and temporally isolated from other cell
processes4 and humans depend on cilia to see, hear, smell,
breathe, excrete, reproduce and develop. Mutations disrupting
them cause several diseases (ciliopathies) including polycystic
kidney disease and other rare disorders like Usher (USH),
Bardet-Biedl (BBS), Meckel-Gru¨ber (MKS) and Jeune (JATD)
syndromes that are of immense recent biological focus5. As many
as 1 in 1,000 people are affected by ciliopathies that lead to
blindness, deafness, heart failure, diabetes, kidney disease, skeletal
defects, infertility and/or cognitive impairment6. This has led to a
renewed interest in cilia and several efforts to understand these
poorly understood organelles.
Studies in animal models and cell culture, show the cilium to
be like a cell antenna, harbouring critical components of Shh,
Wnt, Hippo, Notch and mTor signalling7. Various proteomics
and genetics studies have led to lists of proteins likely to reside in
the cilia7–9 though mechanistic details of processes like ciliary
transport and proteostasis are unknown, and we still lack a
comprehensive picture of the protein machinery operating
in cilia.
Here, we employed affinity proteomics to probe the wiring
of ciliary proteins and integrated the resulting landscape
with disease mutations/variants, cell biology and functional
information. The resulting interactome extends knowledge on
the ciliary machinery, helps to identify new disease-relevant
ciliary proteins and modules, and provides a bounty of new data
to aid the understanding, diagnostics and treatment of these
devastating genetic disorders.
Results
The ciliary landscape. We determined a ciliary protein landscape
by systematic tandem affinity purifications (SF-TAP10) coupled to
mass spectrometry (MS) for 217 proteins, with known/suspected
involvement in ciliary function or disease, in HEK293T cells
(Supplementary Fig. 1; Supplementary Data 1), which are ciliated
(Supplementary Fig. 2), and an effective means to study cilia11.
From the selected baits 91 are known ciliopathy genes and 124 are
gold-standard ciliary proteins12. The 80 baits not in any of these
sets are those that frequently appeared in previous ciliary
proteomes8 or were candidate ciliary proteins from previous
studies (Supplementary Data 1; Supplementary Data 9).
We performed purifications at least twice for 165 baits
(644 total) leading to 41,170 bait–prey pairs involving 4,703
proteins (Supplementary Data 2), with reasonable saturation
(Supplementary Fig. 3). To identify confident interactions, we
adapted the socioaffinity index13 to account for the partial
proteome and weighted protein counts by peptide coverage.
Socioaffinity provides a single measure of the association between
each pair of proteins based on an entire TAP-data set, considering
both the spoke (when one protein retrieves another when tagged)
and the matrix (when two proteins are retrieved by another)
evidence, and the overall frequency of each protein in the data set.
Effectively this gives higher confidence to interactions seen
multiple times, and down-weights ‘sticky’ proteins that are often
seen. Benchmarking these values with known interactions and a
set of negative interactions14 gave excellent sensitivity
and provided false-positive and false-discovery rates (FPR,
FDR) that gave confidence intervals (Supplementary Fig. 4;
Supplementary Data 3). We identified complexes of 3–20 subunits
by clustering the interactions using clique identification
(Supplementary Data 4).
The landscape includes 1,319 proteins and 4,905 interactions
(FDR/FPRr0.1), including 91 of 154 known ciliopathy genes,
134 of 302 gold-standard ciliary proteins and 84 of 362 recently
identified ciliary proteins9. Our approach shows power in
identifying real ciliary components as 16 ciliopathy genes,
23 gold-standard and 53 ciliary proteins not among our
original baits were nonetheless found (Supplementary Data 9).
The socioaffinity index has, as expected13, removed interactions
likely to be the result of missed contaminants or very high protein
abundancies. Specifically, the 16 proteins with the highest
(top 0.1%) median human protein abundancies15 are found
multiple times across a total of 619 (96.2% of the total)
purifications, but only one (vimentin) has any significant
interactions in our network, and the best two (of 12) of these
are known interactions with NEFM/NEFL.
Clustering of these interactions yielded 52 complexes
involving 359 proteins distributed across ciliary and other cellular
processes (Fig. 1; Supplementary Fig. 1; Supplementary Data 4).
Twenty-four complexes have significant overlaps with known
complexes (whether ciliary or not), of which 16 contain canonical
gold-standard12 ciliary components. The remaining 28 are largely
novel, of which 15 contain one or more known ciliary proteins.
Known complexes include those in ciliary transport (IFT-A and -B,
the BBSome and KIF3 complex), organellar organization/
transport (the exocyst, dynactin and dynein), centriole/basal-
body organization (MKS1) and several other not previously
associated with ciliary function (below). Interconnections
between ciliary transport and cytoskeleton/centrosome
complexes, supports the view that canonical ciliary proteins
have roles outside the cilium16. We defined core and
attachment13 subunits for most complexes (Supplementary
Data 4). For instance, the GTPase RALB and BLOC1S2 are
known attachments of the exocyst and IFT-B17,18 complexes,
respectively (Fig. 2a,d). Finer structure for complexes is also
apparent (Fig. 2), including known exocyst sub-complexes17, the
known sub-network involving the progression of NPHP and
RPGR proteins (Fig. 2f)19, and new sub-complexes in
IFT-B (below).
Although we did not determine stoichiometries of the
complexes, comparison of known protein levels across many cell
types15 shows that they are nevertheless stoichiometrically logical:
there are few complex cores where one component has a
wildly different abundance from the others. Overall, the
median differences in abundancies are significantly lower
(t-test Po0.0001) when looking at proteins within complexes
(23.6 p.p.m.) compared with those between complexes
(126 p.p.m.) or involving proteins that were detected in the
screen but not in any significant interactions (140 p.p.m.). This
suggests that the socioaffinity filtering is effective at removing
non-specific components and identifying complexes that are
stoichiometrically sensible.
Proteins and complexes essential to ciliary function. Among the
newly identified complexes, several involve multiple proteins not
previously described to act together. For example, we see the
ciliogenesis transcription factor FOXJ1 (Fig. 2g) in a complex
with Polo-like kinase 1 and the cilia- and flagella-associated
protein 20 (CFAP20). This complex interacts with another
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containing the X-box factors, RFX1-3, and HDAC1 and 2. Other
proteins co-purified with this complex, for example, forkhead box
proteins, TBC1D32/broad minded and CDK20/cell cycle-related
kinase, suggesting they act directly on the transcriptional
regulation of ciliogenesis, which explains their proposed role
in coordination of ciliary assembly20. We also see the ciliary
protein KIAA0556, recently associated with Joubert syndrome, in
complex with kinases ICK and MAK, the latter of which interacts
with IFT-B (Fig. 1b), supporting a role in the IFT-B train21.
Seventeen ciliary proteins (including six IFT subunits)
retrieved subunits of the glucose-induced deficiency (GID) RING
E3 ubiquitin ligase complex, involved in regulating gluco-
neogenesis22, and tagged GID subunits retrieved 18 ciliary
proteins, suggesting a ciliary role for this complex. We found
that GID complex components localized to the ciliary base in
both brain and kidney tissue (Fig. 2d) suggesting a role in
cellular energy homoeostasis in cilia. A general role for the
ubiquitin–proteome system in cilia23 is also supported by the
presence of the anaphase-promoting complex, the proteasome
and eight ubiquitin conjugating/modifying enzymes in our
network (Fig. 2e); absence of several of these proteins also
disrupts ciliogenesis24.
Overall 1,008 of the 1,319 proteins found in our landscape
are not known to be ciliary, though we expect several of these to
play non-ciliary roles. More stringently, 544 non-ciliary proteins
are either in a complex and/or a confident interaction
(FDR/FPRr0.1) with gold-standard proteins (Supplementary
Data 5) of which 77 have an siRNA-induced ciliary phenotype24
and 32 are among 331 novel (out of 371 total) ciliary localized
proteins from a recent proteomics study9. For 39 there is at least
one homozygous missense variant in the UK10K ciliopathies25
data set (377 have heterozygous variants). This subset is an
excellent starting point for new investigations into ciliary function
and disease.
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Figure 1 | Overview of the ciliary landscape. (a) HEK293T cells stained with the ciliary marker ARL13B (green), the transition zone marker
RPGRIP1L (purple), and the axonemal marker acetylated alpha-tubulin (red). Scale bar, 20mm. In the magnifications the scale bar represents 5 mm.
(b) Complexes/proteins identified in this study are depicted by circles and rounded boxes. Rounded boxes show complexes/proteins in the Syscilia
gold-standard ciliary proteins. The edge thickness is proportional to the socioaffinity index, and proteins/complexes are coloured according to whether they
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Architecture of intraflagellar transport complexes. Despite an
established functional connection related to ciliary transport, we
saw no significant direct physical connections between IFT-A and
B. This is in broad agreement with what is currently known as,
despite some early, and partly indirect, evidence of a physical
association26, they are not normally seen to interact27. There are
also comparatively few other proteins that bridge the IFT-A and
B complexes. Apart from the known linker LCA5 (ref. 11), the
only connection we found between them is NUDC, a WD-repeat,
beta-propeller-specific co-chaperone28. Within our un-processed
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purification data, 13/25 proteins that retrieve NUDC (when
tagged and overexpressed) contain WD-repeats (Fisher test
Po0.0001; Supplementary Fig. 5), but only 2/37 proteins
retrieved by tagged NUDC contain WD-repeats, which is
roughly what one would expect from a chaperonin.
Interestingly, when we searched for Gene ontology terms
enriched among 52 proteins targeted by NUDC28, only ciliary,
axoneme, centrosome, and ubiquitination processes were
significant, suggesting this co-chaperone to be particularly
functionally relevant for cilia. The presence of this co-
chaperone is not indicative of non-specific chaperone proteins
(or other parts of the protein synthesis or maintenance
machinery) in our network, as these are effectively filtered by
the socioaffinity metric as observed previously13. For example,
CCT has been proposed to be involved in BBSome assembly29.
We see CCT subunits in 449 purifications, though their
promiscuity means that all 16,331 possible interactions
are insignificant with just nine marginally significant
(FPR/FDRr0.2) interactions all involving known ciliary
proteins, including BBS5 and BBS4.
The IFT-B particle appears to consist of two sub-complexes
(Fig. 3), with IFT88 at the interface. These correspond to
core (IFT-B1), and peripheral subunits described previously30,
though with the latter forming a distinct complex (IFT-B2).
Sucrose density centrifugation and EPASIS31 analyses support
this finding (Fig. 3; Supplementary Fig. 6; Supplementary Data 6).
Additionally, we used structural and interaction information32,33
to identify rare IFT-B missense variants (identified by targeted
resequencing of severe ciliopathy cases), that might affect
interactions in IFT-B (Supplementary Fig. 7) and potentially
contribute to disease severity. Six out of 10 predicted interaction
targeting variants could be purified from HEK293T cells and
compared to wild type (Supplementary Fig. 1; Supplementary
Data 7). Three of them specifically affected one sub-complex
(Fig. 2a; Supplementary Fig. 8). For example, IFT88 p.R607H, a
heterozygous variant in an MKS fetus, leads to a specific loss of
IFT-B1, supporting IFT88 as a bridge between IFT-B1/B2,
and suggesting that this residue might mediate interactions with
IFT-B1. There is no evidence that these variants are recessive or
disease-causing alleles. We expect that they are modifiers affecting
disease severity (for example, as a result of mutational load)34,
and further tests can establish the impact in the context of
causal loci. Regardless of their ultimate genetic meaning, these
observations provide additional support that IFT-B forms two
sub-complexes.
IFT-B components IFT20 and TRAF3IP1 interact with
Dysbindin-1 and BLOC1S2 (Fig. 2a), components of the BLOC-
1 complex, involved in the transport of membrane cargos and
endosomal trafficking. The association of IFT-B components with
periciliary cytoplasm membrane vesicles in dendrites supports
this link35, and the IFT involvement in vesicle transport is
corroborated by its likely protocoatomer origin36. Possibly related
to this, TTC30B (IFT-B) interacts with 20 functionally diverse
transmembrane proteins (Fig. 2a), including the uncharacterized
TMEM41B, which shows a ciliary phenotype: siRNA
downregulation increases and overexpression decreases ciliary
length (Fig. 2a; Supplementary Fig. 9). The lack of functional
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Figure 3 | Identification of IFT-B sub-complexes and edgetic variants. (a)
Socioaffinity-weighted, spring-embedded (cytoscape) layout of IFT-B
proteins with two sub-complexes indicated. (b) Cumulative elution profiles
for IFT-B1/B2 proteins FLAG-purified and analysed by EPASIS in HEK293
cells stably expressing IFT88 or IFT27. Green and blue lines show
components of IFT-B1 and -B2 sub-complexes, respectively. (c) Networks
showing protein depletions in IFT-B comparing mutant to wild type with
TAP-MS. Red arrows denote proteins with variants, and protein size is
proportional negative fold-change. Top left, IFT88 p.R607H, a heterozygous
MKS patient variant leads to a loss of IFT-B1. Bottom left, HSPB11 p.T41I
(heterozygous MKS) at the IFT27 interface, leads to the loss of IFT-B1. Top
right, IFT-B2 subunit, IFT172 p.E1153G (heterozygous in MKS) leads to a
loss of IFT-B2. Bottom right, HSPB11 p.R61S (heterozygous JATD), on the
surface, potentially interacting with an unknown partner, though not at any
known interface affects only HSPB11 itself. Green and blue nodes represent
components of the IFT-B1 and -B2 sub-complexes, respectively.
Figure 2 | Complexes and networks within the landscape. (a) Detailed network of IFT-B1/2 and MAK/ICK/KIAA0556; IFT-B is linked to IFT-A by NUDC,
and to complex KIF3 by SSNA1. The IFT-B protein TTC30B interacts with multiple membrane proteins. One of those, TMEM41B, was further analysed and
shows a ciliary length phenotype upon modulation of expression by siRNA knock-down and overexpression. For both, knockdown and overexpression,
biological triplicates were analysed and a t-test was performed. P values below 0.01 are represented by ** and below 0.001 by ***. Error bars represent the
s.e.m. (b) Detailed interaction network of the KIF3 complex and Complex:15, with SLC9A2R2 bridging ciliary processes. (c) Detailed interactions between
Dynein and Dynactin intermediated by the HSF1/HSPA1L/MAPRE2 linker complex. (d) Muskelin/RanBP9/CTLH complex (GID complex in Yeast) network
showing core, attachments and links to several other complexes, mediated by RAB8A. Immunofluorescence demonstrates the localization of two GID
components, GID8 and MKLN1 (red arrows in the network) to the ciliary base: MKLN1 in kidney tubule epithelial cells (anti-MKLN1, left panel, red); GID8
(right panel, green) in multi-ciliated brain ependymal cells. DAPI staining (blue) marks the nucleus, GT335 co-staining (green or red) marks the cilium.
Scale bars represent 10mm. (e) Complex:21 and 31 containing several ubiquitin conjugating or modifying enzymes in interaction with the GID and exocyst
complexes. (f) Elaborated view of the sub-network involving the NPHP1-NPHP4-RPGRIPL/PDE6D/RPGR complex, and its association with the complexes
IQ/CALM1, KIF3, COP9 signalosome, and Complex:15. (g) Ciliogenesis transcription factor FOXJ1 stably interacts with PLK1 (Polo-like kinase 1) and
CFAP20, and is linked to the FOXJ/RFX complex and Complex:15.
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commonalities among these membrane proteins raises the
possibility that they could be IFT-B cargos targeted by TTC30B.
Proteins bridging ciliary complexes. Several proteins appear to
link important ciliary complexes or proteins (Fig. 1). For example,
SSNA1, potentially in collaboration with LCA5, both have ciliary
transport phenotypes11 and link IFT-B to Dynein and KIF3
complexes. We also see RAB8A interacting with RAB3IP and the
TRAPP complex as known37, but also with the GID and exocyst
complexes and the membrane protein stomatin, involved in the
formation of membrane protrusions (Fig. 2d), suggesting new
roles in membrane protein trafficking38,39. SLC9A3R2, a scaffold
protein not associated with ciliary function but which interacts
with seven gold-standard proteins (Fig. 2b), interacts with known
partners YAP1 and CTNNB1 plus several proteins involved
in Usher syndrome and non-syndromic deafness and the COP9
signalosome (Fig. 2b) that hint at roles in actin attachment/
polarization40, DNA damage response or proteasomal
degradation41. Finally, there are several proteins linking
complexes to the kinetochore, such as microtubule-associated
protein RP/EB family members 1 and 2 (MAPRE1,2) and
platelet-activating factor acetylhydrolase IB subunit alpha
(PAFAH1B1), which lie between IFT-B, GID and the dynactin
and dynein kineotochore/microtubule complexes (Fig. 2c).
Comparison with previous studies. The BioPlex data set42,
which currently contains 5,087 affinity purifications from
HEK293T cells, has 81 of the 217 baits we tagged here.
Calculating socioaffinities gives 63,018 confident interactions in
BioPlex, of which 421 overlap with our 4,905 interactions
(considering the entire BioPlex bait–prey pairs the overlap
is 271). Another recent study in HeLa cells involving 1,125
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Figure 4 | 3M Syndrome is a ciliopathy. (a) Schematic showing comparison of interactome to disease genes with the top scoring diseases shown (orange
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GFP-tagged proteins coupled to quantitative proteomics
identified 31,944 significant protein interactions43 also with a
low overlap: 239 common interactions, principally involving the
GID, dynactin, CNOT, MCM and exosome complexes (which
contain the 28 common baits). The low overlaps highlight the
need for specific sub-proteome targeting to uncover interactions
of interest as targeting a small subset of baits is insufficient to
resolve complexes and interactions fully. The subtleties of
architecture that we see in the IFT-B and exocyst complexes are
also not apparent in the BioPlex set (and disappear when we
simulate fewer baits/repetitions; Supplementary Figs 10 and 11),
highlighting the value of repeated reverse tagging to provide
high-resolution interactomes.
New ciliopathies emerging from the organellar landscape. The
variants affecting IFT-B (above) illustrate how genetic changes
can inform mechanistic biology. A natural question is whether
this works in reverse: can our ciliary landscape inform clinical
genetics? Our interactome (1,319 proteins) overlaps with gene
sets from 35 genetic diseases (Fig. 4) of which 11 are known
ciliopathies (Supplementary Data 8), and others are ciliopathy
related (for example, ‘Deafness’ or ‘Mental Retardation’) and
several, including Amyotrophic lateral sclerosis, Hermansky-
Pudlak, Nephrotic and 3M syndromes are potentially new
ciliopathies. We did not tag any of the three known 3M syndrome
(‘3M complex’44) -associated proteins though two (OBSL1 and
CCDC8) are in our landscape, and the third (CUL7) was detected
in multiple purifications, but made no confident interactions.
siRNA knock-downs (validated by qPCR; Supplementary Fig. 12)
reduced ciliated fractions in mpkCCD cells, which could be
rescued by co-expressing human orthologs (Fig. 4; Supplementary
Fig. 12). Fibroblasts from a skin biopsy of a 3M case (CUL7
homozygous mutations), known to disrupt ubiquitination45, had
significantly fewer cilia than controls (Fig. 4; Supplementary
Fig. 13; ciliary length unchanged). Cilia could also be restored by
overexpression of wild type, but not mutant CUL7 (Fig. 4). This
ciliary phenotype suggests that 3M syndrome is indeed a
ciliopathy.
Discussion
The rich landscape including new ciliary-associated proteins,
interactions and complexes, when coupled to the growing array of
genetic and functional information, will undoubtedly lead to
many additional insights into ciliary function and disease. Our
organelle-specific interactome also shows considerable power to
suggest new genetic diseases (for example, 3M syndrome) likely
related to ciliary dysfunction. Identifying novel ciliopathies can
have an immediate impact on diagnostics and treatments. For
instance, diagnoses can be aided by examining ciliary frequency
in young patients’ cells46.
Targeted, repeated, reverse-tagged, TAP-MS proteomics
coupled to socioaffinity uncovers physically meaningful interac-
tions not always apparent in high-throughput studies42,43.
Moreover, the success of this strategy at uncovering finer sub-
structures has certain implications for structural biology. Indeed,
since the acceptance of this manuscript a discrete structure for
many of our IFT-B2 components has provided additional support
for this approach47. Whole proteome data of this quality could
provide unprecedented insights into the architecture of many
additional protein complexes. The edgetic48 disease variants
affecting specific sub-complexes also shows the complementarity
of genetic and mechanistic investigations. A larger study of
41,000 disease mutations has shown that many affect protein–
protein interactions1 and additional studies like that we have
performed here, in concert, for example, with larger complex data
sets42, could also illuminate more generally how disease variants
impact protein function.
Overall, this study has demonstrated the great comple-
mentarity of proteomics and genetics and the power of focussing
on a disease-relevant organelle. As such, this work provides a
framework for powerful future applications in biomedicine.
Methods
Affinity purifications. To determine the ciliary protein network, we selected a set
of 217 proteins, among which 124 are Syscilia gold standard proteins, 91 are
ciliopathy-associated proteins, and 80 are proteins with predicted ciliary function.
The proteins were overexpressed in HEK293T cells, fused to a SF-TAP tag to
enable tandem affinity purification of the associated protein complexes. The cells
were lysed and after clearance of the lysate by centrifugation, the lysate was sub-
jected to a two-step purification via the StrepII-tag, followed by an enrichment
using the FLAG moiety. Competitive elution was achieved by addition of the FLAG
peptide. The eluate was precipitated by methanol–chloroform and then subjected
to mass spectrometric analysis.
Mass spectrometry. Following precipitation, SF-TAP-purified complexes were
solubilized and proteolytically cleaved using trypsin. The resulting peptide samples
were desalted and purified using stage tips before separation on a Dionex RSLC
system. Eluting peptides were directly ionized by nano-spray ionization and
detected by a LTQ Orbitrap Velos mass spectrometer. Mascot was used to search
the raw spectra against the human SwissProt database for identification of proteins.
The Mascot results were post validated by Scaffold which employs the protein
prophet algorithm.
Identification and label-free quantification for EPASIS and sucrose density
centrifugation data was performed with MaxQuant. The peptide and protein
false-discovery rates were set to 1% and only unique peptides were used for
quantification.
Network and complex delineation. We modified the socioaffinity metric13 to
consider protein coverage and to account for the lack of complete proteome
tagging. We computed false-positive and false-discovery rates using a gold standard
of known interactions and a systematically derived set of negative interactions.
We applied a Hierarchical Clique Identification approach to cluster proteins and
defined attachments as proteins having at least two significant links to the cluster
(without being in the cluster itself).
Sub-complex analysis. For both, sucrose density gradient centrifugation and
EPASIS, the SF-TAP-tagged bait proteins were stably expressed in HEK293 cells
and the complexes were affinity purified by FLAG purification. For sucrose
density centrifugation, the complexes were eluted by addition of FLAG peptide,
and sub-complexes were separated by a discontinuous gradient and fractionated
after centrifugation at 166,000gAV (ref. 49). The fractions were precipitated and
subjected to label-free mass spectrometric analysis.
EPASIS makes use of controlled destabilization of protein–protein interactions
by the addition of low concentrations of SDS (Supplementary Fig. 6). The purified
complexes were immobilized on FLAG beads. By applying a step gradient,
interactions of bait protein and sub-complexes are sequentially destabilized
and thereby sub-complexes eluted. Each fraction was subjected to label-free
quantification by mass spectrometry before the quantitative data were used
to calculate elution profile distances to detect co-eluting sub-complexes.
Affinity purification. In total 217 Strep-FLAG tandem affinity purification
(SF-TAP)10 expression constructs were generated (Supplementary Data 1).
Bait protein selection was based on the association of proteins with ciliopathies
(including mutant vertebrates showing ciliopathy features) or involvement in IFT.
In addition, we selected part of our candidate list of ciliary proteins which is a
compilation of a subset from the ciliary proteome database8 (type: non-reciprocal;
e-value cut-off: 1E 10; study selection all, Z4 studies) and candidate ciliary
proteins resulting from previous studies in our labs. Gateway-adapted cDNA
constructs were obtained from the Ultimate ORF clone collection (Thermo Fisher
Scientific) or generated by PCR from IMAGE clones (Source BioScience) or human
marathon-ready cDNA (Clontech) as template and cloning using the Gateway
cloning system (Thermo Fisher Scientific) according to the manufacturer’s
procedures followed by sequence verification.
HEK293T cells were grown in DMEM (PAA) supplemented with 10% fetal
bovine serum and 0.5% penicillin/streptomycin. Cells were seeded, grown
overnight and then transfected with the corresponding SF-TAP-tagged DNA
constructs using PEI reagent (Polysciences) according to the manufacturer’s
instructions. Forty-eight hours later, cells were harvested in lysis buffer containing
0.5% Nonidet-P40 (NP-40), protease inhibitor cocktail (Roche), and phosphatase
inhibitor cocktails II and III (Sigma-Aldrich) in TBS (30mM Tris-HCl, pH 7.4 and
150mM NaCl) for 20min at 4 C. Cell debris and nuclei were removed by
centrifugation at 10,000g for 10min.
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For SF-TAP analysis, the cleared supernatant was incubated for 1 h at 4 C with
Strep-Tactin superflow (IBA). Subsequently, the resin was washed three times in
wash buffer (TBS containing 0.1% NP-40 and phosphatase inhibitor cocktails II
and III, Sigma-Aldrich). Protein baits were eluted with Strep-elution buffer (2mM
desthiobiotin in TBS). For the second purification step, the eluates were transferred
to anti-Flag M2 agarose (Sigma-Aldrich) and incubated for 1 h at 4 C. The beads
were washed three times with wash buffer and proteins were eluted with FLAG
peptide (200 mgml 1, Sigma-Aldrich) in TBS. After purification, the samples were
precipitated with chloroform and methanol and subjected to in-solution tryptic
cleavage50. Precipitated protein samples were dissolved in 30 ml, 50mM
ammonium bicarbonate (Sigma-Aldrich), supplemented with 2% RapiGest
(Waters) before 1 ml 100mM DTT (Merck) was added. After incubation at 60 C
for 10min, 1 ml, 300mM 2-iodacetamide was added followed by incubation at
room temperature for 30min in the dark. Before overnight incubation at 37 C,
1 mg of trypsin (Sigma-Aldrich, sequencing grade) was added. The reaction was
stopped by addition of trifluoracetic acid to a final concentration of 1%.
Generation of stable cell lines. For stable HEK293 cells, cells were cultivated as
indicated above and transfected with the corresponding DNA construct using PEI
reagent. After 48 h, the medium was exchanged by growing medium supplemented
with G418 (Biochrom, 750mgml 1). The cells were cultivated forB3 weeks, until
the transiently transfected cells died. The medium was exchanged regularly to
ensure normal growth. Afterwards, the cells were split in a ratio of 1:100 and
cultivated until single colonies were observed. Colonies were transferred to six-well
plates and cultivated to confluency. For evaluation, a part of the cells was lysed
and applied to western blot analysis, using an anti-FLAG-M2-HRP antibody
(Sigma-Aldrich) for detection of the expressed SF-TAP-fusion protein.
Mass spectrometric analysis. Qualitative mass spectrometry. After precipitation
of the proteins by methanol–chloroform, a tryptic in-solution digestion was
performed as described above50. LC–MS/MS analysis was performed on a
NanoRSLC3000 HPLC system (Dionex) coupled to a LTQ or to a LTQ Orbitrap
Velos mass spectrometer (Thermo Fisher Scientific) by a nano-spray ion source.
Tryptic peptide mixtures were automatically injected and loaded at a flow rate of
6 ml min 1 in 98% buffer C (0.1% trifluoroacetic acid in HPLC-grade water) and
2% buffer B (80% actetonitrile and 0.08% formic acid in HPLC-grade water) onto a
nanotrap column (75 mm i.d. 2 cm, packed with Acclaim PepMap100 C18, 3 mm,
100Å; Dionex). After 5min, peptides were eluted and separated on the analytical
column (75 mm i.d. 25 cm, Acclaim PepMap RSLC C18, 2 mm, 100Å; Dionex) by
a linear gradient from 2 to 35% of buffer B in buffer A (2% acetonitrile and 0.1%
formic acid in HPLC-grade water) at a flow rate of 300 nlmin 1 over 33min for
EPASIS samples, and over 80min for SF-TAP samples. Remaining peptides were
eluted by a short gradient from 35 to 95% buffer B in 5min. The eluted peptides
were analysed by using a LTQ Orbitrap XL,
or a LTQ OrbitrapVelos mass spectrometer. From the high-resolution mass
spectrometry pre-scan with a mass range of 300–1,500, the 10 most intense peptide
ions were selected for fragment analysis in the linear ion trap if they exceeded an
intensity of at least 200 counts and if they were at least doubly charged. The
normalized collision energy for collision-induced dissociation was set to a value of
35, and the resulting fragments were detected with normal resolution in the linear
ion trap. The lock mass option was activated and set to a background signal with a
mass of 445.12002 (ref. 51). Every ion selected for fragmentation was excluded for
20 s by dynamic exclusion.
For qualitative results the raw data were analysed using Mascot (Matrix Science,
version 2.4.0) and Scaffold (version 4.0.3, Proteome Software). Tandem mass
spectra were extracted, charge state deconvoluted and deisotoped by
extract_msn.exe version 5.0. All MS/MS samples were analysed using Mascot.
Mascot was set up to search the SwissProt_2012_05 database (selected for Homo
sapiens, 2012_05, 20,245 entries) assuming the digestion enzyme trypsin. Mascot
was searched with a fragment ion mass tolerance of 1.00Da and a parent ion
tolerance of 10.0 p.p.m. Carbamidomethyl of cysteine was specified in Mascot as a
fixed modification. Deamidation of asparagine and glutamine and oxidation of
methionine were specified in Mascot as variable modifications. Scaffold was used to
validate MS/MS based peptide and protein identifications. Peptide identifications
were accepted if they could be established at 480% probability by the Peptide
Prophet algorithm52 with Scaffold delta-mass correction. Protein identifications
were accepted if they could be established at greater than 95.0% probability and
contained at least two identified peptides. Protein probabilities were assigned by the
Protein Prophet algorithm53. Proteins that contained similar peptides and could
not be differentiated based on MS/MS analysis alone were grouped to satisfy the
principles of parsimony. Furthermore, proteins were only considered to be specific
protein complex components if they were not detected in the control experiments.
Data were exported from Scaffold (Proteome Software) to tab-delimited protein
reports and curated into data templates for database integration with other data
and further analysis. Although great care was taken to avoid sample carryover
during the experimental procedure of TAP and MS analysis, we noted occasionally
carryover of bait proteins in a series of TAP experiments analysed consecutively by
MS. Therefore we removed all bait proteins per series of experiments from the MS
results (127 protein identifications in total) and experiments were replicated for
known IFT and ciliopathy-associated proteins making sure that bait proteins were
in unique combinations in new series of experiments. This allowed us to detect
protein interactions between proteins that are both bait and prey proteins in our
experiments.
Quantitative mass spectrometry. For quantitative analysis, MS raw data were
processed using the MaxQuant software (version 1.5.0.3 (ref. 54)). Trypsin/P was
set as cleaving enzyme. Cysteine carbamidomethylation was selected as fixed
modification and both methionine oxidation and protein acetylation were allowed
as variable modifications. Two missed cleavages per peptide were allowed. The
peptide and protein false-discovery rates were set to 1%. The initial mass tolerance
for precursor ions was set to 6 p.p.m. and the first search option was enabled with
10 p.p.m. precursor mass tolerance. The fragment ion mass tolerance was set to
0.5 Da. The human subset of the human proteome reference set provided by
SwissProt (Release 2012_01 534,242 entries) was used for peptide and protein
identification. Contaminants like keratins were automatically detected by enabling
the MaxQuant contaminant database search. A minimum number of 2 unique
peptides with a minimum length of seven amino acids needed to be detected
to perform protein quantification. Only unique peptides were selected for
quantification. For label-free quantification the minimum LFQ count was set to 3,
the re-quantify option was chosen. The option match between runs was enabled
with a time window of 2min, fast LFQ was disabled.
Network and complex delineation. Socioaffinity index and definition of
thresholds. The TAP-MS data includes baits preys together with the unique
peptide counts and the sequence coverage for each protein identified. Before any
consideration we removed a set of potential/known contaminant proteins (ALB,
CALD1, CDSN, DCD, DSP, DSC1, DSC2, DSC3, DSG1, DSG2, DSG3, DSG4,
EOMES, EPPK1, EVPLL, EVPL, GSDMA, GSDMB, GSDMC, GSDMD, HRNR,
KRT10, KRT12, KRT13, KRT14, KRT15, KRT16, KRT17, KRT18, KRT19, KRT20,
KRT23, KRT24, KRT25, KRT26, KRT27, KRT28, KRT39, KRT40, KRT9, KRT31,
KRT32, KRT2, KRT76, KRT77, KRT1, KRT3, KRT4, KRT5, KRT6A, KRT6B,
KRT6C, KRT71, KRT72, KRT73, KRT74, KRT75, KRT78, KRT79, KRT7, KRT80,
KRT8, KRTCAP3, KCT2, KPRP, KRTAP10-1, KRTAP10-2, KRTAP10-3,
KRTAP10-4, KRTAP10-5, KRTAP10-6, KRTAP10-7, KRTAP10-8, KRTAP10-9,
KRTAP10-10, KRTAP10-11, KRTAP10-12, KRTAP11-1, KRTAP12-1,
KRTAP12-2, KRTAP12-3, KRTAP12-4, KRTAP13-1, KRTAP13-2, KRTAP13-3,
KRTAP13-4, KRTAP15-1, KRTAP16-1, KRTAP17-1, KRTAP19-1, KRTAP19-2,
KRTAP19-3, KRTAP19-4, KRTAP19-5, KRTAP19-6, KRTAP19-7, KRTAP19-8,
KRTAP20-1, KRTAP20-2, KRTAP20-3, KRTAP20-4, KRTAP21-1, KRTAP21-2,
KRTAP21-3, KRTAP22-1, KRTAP22-2, KRTAP23-1, KRTAP24-1, KRTAP25-1,
KRTAP26-1, KRTAP27-1, KRTAP29-1, KRTAP4-11, KRTAP4-12, KRTAP5-10,
KRTAP5-11, KRT87P, KRTAP1-1, KRTAP1-3, KRTAP1-4, KRTAP1-5,
KRTAP2-1, KRTAP2-2, KRTAP2-3, KRTAP2-4, KRTAP3-1, KRTAP3-2,
KRTAP3-3, KRTAP4-1, KRTAP4-2, KRTAP4-3, KRTAP4-4, KRTAP4-5,
KRTAP4-6, KRTAP4-7, KRTAP4-8, KRTAP4-9, KRTAP5-1, KRTAP5-2,
KRTAP5-3, KRTAP5-4, KRTAP5-5, KRTAP5-6, KRTAP5-7, KRTAP5-8,
KRTAP5-9, KRTAP6-1, KRTAP6-2, KRTAP6-3, KRTAP7-1, KRTAP8-1,
KRTAP9-1, KRTAP9-2, KRTAP9-3, KRTAP9-4, KRTAP9-6, KRTAP9-7,
KRTAP9-8, KRTAP9-9, KRT34, KRT35, KRT36, KRT37, KRT38, KRT81, KRT82,
KRT83, KRT84, KRT85, KRT86, KRT222, KRT33A, KRT33B, KRTCAP2,
KRTDAP, LALBA, PPL, PKP1, PKP2, PKP3, PKP4, JUP, PVALB, UPK1A,
UPK1B, UPK2, UPK3A, UPK3B and UPK3BL; interestingly, interactions involving
these behaved very much like negative interactions when we performed the ROC
analysis below). To identify protein–protein relationships most supported by the
TAP-MS observations, we derived a modified socioaffinity index3,13, which is a
sum of log-odds values that considers the frequency of protein pairs in the data set,
either as bait–prey (spoke) or prey–prey (matrix) observations, and the overall
frequency of proteins in the entire data set, which avoids the need to explicitly
exclude ‘sticky’ proteins13. We modified the index to account for peptide coverage
by first excluding those proteins where coverage was below 2% and then by using
the coverage ratio (0–1) as counts in the socioaffinity calculation.
To benchmark these socioaffinity indices, we defined a set of positive
interactions from protein interaction databases55: IntAct, BIND, BioGrid, DIP,
Mint, HPRD and Uniprot. We required that interactions were independently
reported at least three times either from different sources or by different methods
indicating direct physical interactions. All of our selected databases register the
interaction detection methods following the terms of OLS (http://www.ebi.ac.uk/
ontology-lookup/56). Among all of the ‘molecular interaction’ terms, we selected
165 to be related to physical interactions. Our positive interaction set also excludes
interactions detected by TAP-like methods. When more than 10 interactions in one
publication share the same interaction ID or interactor, these were excluded from
our set of positives. We defined a set of negative interactions from a set derived by
analysis of high-throughput yeast two-hybrid studies14. Overall, we had 658,352
positive and 894,213 negative interactions.
We computed true-positive and false-positive rates (TPR and FPR) for
decreasing socioaffinity thresholds. Inspection showed that we obtained very
different curves depending on the nature of the protein pairs considered, with
reverse tagging (that is, data when both proteins have been tagged) having different
thresholds and generally better ROC plots (Supplementary Fig. 4), thus we
considered the three classes (both-tagged, one-tagged or none-tagged) separately.
Also because of a lack of complete reverse tagging, and general unreliable estimates
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about the size of the interactome, we are unable to estimate the relative numbers of
positives and negatives. For this reason, we took the stringent view of requiring
both FPR (that is, fraction of negatives predicted by socioaffinity as positives) and
false-discovery rate (FDR, or the fraction of predictions that are false positives) to
be below a common threshold (0.1, 0.05, 0.01). Inspection showed that this gave a
reasonable sensitivity but also avoided situations of a multitude of interactions
involving common values that had FPR values near the threshold. We compared
the coverage-weighted to binary (that is, protein present or not) counts for the
socioaffinity calculation, and though the difference was marginal overall, inspection
of the resulting networks showed a better resolution of sub-complexes known in
the literature (for example, Exocyst, RPGR, see main text), which prompted us to
use the weighted values.
Clustering to identify putative complexes. By considering each type of interaction
(none, one or both proteins tagged) independently in the computation of the FPR
and FDR values resulted in a non-monotonic relationship between FPR, FDR and
socioaffinity indices. To take into account both FDR and socioaffinity during
clustering we devised a score so that FDR is monotonically decreasing with respect
to the new score:
SAFDRði; jÞ ¼ maxðk;lÞ:FDRðk;lÞ4FDRði;jÞ SAFDRðk; lÞþ SAði; jÞ minðk;lÞ:FDRðk;lÞ¼FDRði;jÞ SAðk; lÞ
The new score was computed iteratively starting with the interactions with the
highest FDR value. For these interactions there are no protein pairs with higher
FDR and the first term in the above equation is zero.
Protein complexes were predicted from the weighted PPI network using
Hierarchical Clique Identification (HCI). The algorithm merges proteins in clusters
based on their interaction scores using a hierarchical agglomerative clustering
(HAC) approach that allows overlapping clusters. HCI starts by considering a
weighted graph constructed from experimental data. In this graph, nodes
correspond to clusters and edge weights are measures of similarity (for example,
socioaffinity scores). Initially each protein is assigned to a cluster. At each iteration
the algorithm selects the clusters to be combined and then updates the weights of
the edges between clusters. For the selection of the clusters to be merged, an
unweighted network is constructed by considering the edges with a weight equal to
the maximum weight. Then the algorithm mines this network for maximal cliques,
that is, cliques that are not contained in larger cliques. The extracted maximal
cliques define the set of clusters to be combined. Nodes corresponding to merged
clusters are removed from the network and new nodes are introduced for the new
clusters. In general, linkage criteria similar to those used in HAC could also be used
in HCI. In this study clusters are connected if the union of their members forms a
clique and the weight of the edge connecting them is equal to the maximum weight
of the edges connecting their non-common members. Formally, the linkage
criterion between two clusters X and Y is given by:
d X;Yð Þ ¼ max
x2X nY;y2Y nX
dðx; yÞ if 8x 2 X;8y 2 Y x; yð Þ 2 E
It is clear that only pairs of clusters that form a clique upon merging are connected
in the new graph. This may result in the loss of the highest weighted edges of some
nodes. This happens for instance when the best neighbour of a node is merged in a
cluster, which is not fully connected with the node. To avoid merging of the node
based on lower weighted edges, whenever a node loses its highest weighted edges it
is removed from the graph. The entire procedure terminates when the graph
becomes disconnected or when a score threshold is reached, which is the case here.
Except for the score threshold an additional filtering step was used to identify
the sub-structure of the predicted complexes, if any. This was achieved by using
Dirichlet process mixture (DPM) model57. DPM is a probability mixture model
with an infinite number of components, which are mixed according to a stochastic
process called Dirichlet process. DPM has been extensively used for data clustering
due to its property that the stochastic process for mixture proportions almost
surely produces a finite number of distributions. In DPM a cluster i is described by
a parametric distribution f ð j yiÞ, in our case Gaussian. The mixture model has
the form yj 
PK
i¼1 pi f ð j yiÞ, where K is the number of clusters and pi the
mixture proportion of the distribution f ð j yiÞ. Moreover, the distribution
parameters yi are drawn from a base distribution G0. While the initial number of
components K is infinite, DPM ensures a finite number of components by properly
selecting the mixture proportions pi from a dirichlet distribution.
For each cluster that was identified in the first step the distance matrix,
consisting of the socioaffinity scores for all protein pairs in the cluster, was
constructed. DPM was then used to identify sub-complexes from the distance
matrix. Variational inference58 was used to fit the DPM to the data and to identify
the optimal clustering. If the DPM was consisting of a single component then the
cluster was left intact. Otherwise, the branch of the dendrogram corresponding to
the specific cluster was traced backwards to identify the subclusters that best match
the DPM clustering.
Gene enrichment analyses. We extracted various gene/protein sets either from
Gene Ontology or from Uniprot. From the latter we extracted complexes by
identifying canonical gene names within Subunit/Complex descriptions for
particular Uniprot accessions, and extracted genes related to genetic diseases from
specific mutations linked to particular disease types (for example, BBS2) adding
generic (for example, BBS) names where appropriate. To compute enrichment we
used a Fisher exact test corrected for multiple testing where we estimated an
effective total of sets (in each class, for example, Complexes, Diseases, etc.) by
considering sets sharing480% overlapping genes/proteins to be the same set (that
is, to avoid over-correction). A tool for computing this enrichment for human
genes/proteins on these data sets (and others including the complexes determined
previously) is available and http://getgo.russelllab.org.
IFT-B sub-complex analysis. Sucrose density gradient centrifugation. Sucrose
gradients for density centrifugation were prepared in 2ml centrifugation tubes.
250 ml of each concentration (20/17/14/11/8/5% sucrose) were discontinuously
applied to the tube and overlaid with the pooled eluates from two individual
SF-TAP purifications from a HEK293 cell line stably expressing IFT88-SF-TAP.
After centrifugation at 166,000gAV for 4 h in a swing-out rotor (Beckman TLS65),
the gradient was fractionated by pipetting into 125ml fractions49. The fractions
were precipitated by methanol–chloroform and subjected to label-free
quantification by mass spectrometry.
EPASIS. For protein complex destabilization the cleared lysates from
HEK293 cells, stably expressing IFT88-SF-TAP, respectively, IFT27-SF-TAP were
transferred to anti-FLAG M2 agarose (Sigma-Aldrich). After 1 h of incubation,
the resin was washed three times using wash buffer (TBS containing 0.1%
NP-40 and phosphatase inhibitor cocktails II and III, Sigma-Aldrich). For the
SDS-destabilization of the protein complexes, the resin was then incubated 3min
with each concentration of SDS (0.00025, 0.0025, 0.005, 0.01 and 0.1%) in SDS-
elution buffer (TBS containing phosphatase inhibitor cocktails II and III) at 4 C.
The flow through was collected and precipitated by methanol–chloroform. After
every elution step a single wash step was performed. Subsequently to the SDS
gradient, the remaining proteins were eluted from the resin by incubation for 3min
with FLAG peptide (200 mgml 1; Sigma-Aldrich) in wash buffer. The fractions
were subjected to label-free quantification by mass spectrometry.
Statistical data analysis was carried out in R59 by calculating the elution profile
distance for each protein to the consensus profile for IFT-B1 and IFT-B2 (ref. 31).
For each cell line, stably expressing IFT27, IFT88 or SF Control, six replicated
EPASIS experiments were performed (108 measurements). Unique peptides with a
minimum peptide length of seven amino acids were identified by searching against
the forward and a reversed version of the database which indicates an average
peptide false-positive identification rate of 0.17% for the experiments.
Without filtering proteins were detected for both, the forward and the reverse
search, leading to an average indicated protein false-positive identification rate of
0.74 % (Supplementary Table 6). To reduce the number of false-positive protein
identifications, proteins were considered as detected, if they were identified by at
least two unique peptides, had a minimal MS/MS spectra count of three and were
not flagged as contaminant by MaxQuant. Proteins that were detected in the
control and the IFT27/IFT88 experiments, were tested using spearman’s
test and excluded from further considerations if they showed a significant
(Po¼ 0.05) correlation between both experiments. Finally, proteins had to
be present in at least 5/6 (83.33%) repeated experiments, resulting in a high
confident list of 45 proteins for IFT27 and 19 proteins for IFT88 that were
further analysed.
Protein intensities for all SDS concentrations of an experiment were combined
and the values log2-transformed. To investigate the linear relationship between
data points, regression lines determined by minimizing the sum of squares of the
Euclidean distance of points to the fitted line (‘orthogonal regression’). Correlations
between repeated experiments were estimated using the Pearson correlation
coefficient together with its 95% confidence interval. To investigate the safe
isolation of elution profiles for different SDS concentrations, Spearman’s
correlation scores were calculated. Consensus profiles of known marker protein
groups (Supplementary Table 6) were calculated by averaging the normalized
cumulative intensities of the protein group per concentration step for all
experiments. Elution profile distances (EPD) to consensus profiles were calculated
for all detected proteins. A stepwise (n¼ 1,000) parameter search was performed to
estimate the optimal EPD threshold to maximize the specificity and sensitivity to
assign known sub-complex members to the consensus profile. To perform non-
metric multidimensional scaling the elution profile distances were averaged across
the replicated (n¼ 6) experiments and Euclidean distances between them
calculated. A stable solution was estimated by using random starts and the best
ordination (stress: 0.03 IFT27; 0.01 IFT88) selected.
Rare variant discovery in the Syscilia cohort. As part of our ongoing investi-
gation of mutational burden in ciliopathies, we conducted bidirectional Sanger
sequencing of coding regions and splice junctions of IFT-B encoding genes
(IFT172, IFT88, IFT81, IFT80, IFT74, IFT57, TRAF3IP1, IFT52, IFT46, IFT27,
HSPB11, RABL5, IFT20 and CLUAP1) in a previously described ciliopathy cohort60
according to standard methodology. The Duke University Institutional Review
Board approved human subjects research, and DNA samples were ascertained
following informed consent. PCR products were sequenced with BigDye
Terminator v3.1 chemistry on an ABI 3,730 (Applied Biosystems), sequences
were analysed with Sequencher (Gene Codes), and variants were confirmed by
resequencing and visual assessment of chromatograms. Primer sequences and PCR
conditions are available upon request.
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Identifying disruptive variants at complex interfaces. We selected 10 IFT-B
variants from the rare variant data set identified in ciliopathy cases (Syscilia cohort)
as candidates to affect IFT architecture by an analysis of the structural features
known or predicted for these subunits (Supplementary Data 7). We used the
Mechismo32 system and identified two variants at or near the interface (IFT27
p.R131Q and HSPB11 p.T41I) and a third on the surface of HSPB11 (p.R61S) but
far away from this interface (and potentially a candidate to bind different proteins).
Though there were no other structures on which to confidently model IFT
subunit interfaces, the fact that most of the subunits contain WD- or TPR repeats
provided the means to use the location of common binding sites in these families to
predict variants that might affect the interaction with a protein, even if the specific
protein partner is not known. To do this we first defined domains by Pfam61,
TPRpred62 and manual refinements were applied to define boundaries for WD-
repeats in IFT172, and for TPR repeats in IFT88, and IFT172. We then aligned the
sequences automatically coupled to manual editing and identified variants at or
near the favourite binding site for WD-repeats (the top-side of the propeller33). For
TPR repeats, binding site residues were defined by side-chain to peptide distances
within a representative set of TPR repeats (from PDB codes 4n3a, 2lsv, 4buj, 1a17
and 1elr) superimposed and aligned using STAMP63. This alignment and a
representative average structure showing the binding sites as depicted in
Supplementary Fig. 7.
Differential AP-MS to compare variants to wild-type proteins. Protein com-
plex comparison was done essentially as described before11. For SILAC labelling,
HEK293T cells were grown in SILAC DMEM (PAA) supplemented with 3mM L-
glutamine (PAA), 10% dialyzed fetal bovine serum (PAA), 0.55mM lysine and
0.4mM arginine. Light SILAC medium was supplemented with 12C6, 14N2 lysine
and 12C6, 14N4 arginine. Heavy SILAC medium was supplemented with either 13C6
lysine and 13C6, 15N4 arginine or 13C6, 15N2 lysine and 13C6, 15N4 arginine. Proline
(0.5mM) was added to all SILAC media to prevent arginine to proline
conversion64. All amino acids were purchased from Silantes. SF-TAP-tagged
proteins and associated protein complexes were purified from HEK293T cells10. To
this end, HEK293T cells, transiently expressing the SF-TAP-tagged constructs were
lysed in lysis buffer containing 0.5% Nonidet-P40, protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktails II and III (Sigma-Aldrich) in TBS
(30mM Tris-HCl (pH 7.4), 150mM NaCl), for 20min at 4 C. After sedimentation
of nuclei at 10,000g for 10min, the protein concentration of the cleared lysates was
determined by Bradford before equal protein amounts were transferred to Strep-
Tactin-Superflow beads (IBA) and incubated for 1 h. The resin was washed three
times with wash buffer (TBS containing 0.1% NP-40, phosphatase inhibitor
cocktail II and III). The protein complexes were eluted by incubation for 10min in
Strep-elution buffer (IBA). The eluted samples were combined before
concentration using 10 kDa cut-off VivaSpin 500 centrifugal devices (Sartorius
Stedim Biotech) and pre-fractionation using SDS–PAGE and in-gel tryptic
cleavage65.
Yeast two-hybrid system. A GAL4-based yeast two-hybrid system was used to
screen for binary protein–protein interactions. Yeast two-hybrid constructs were
generated according to the manufacturer’s instructions using the Gateway cloning
technology (Thermo Fisher Scientific) by LR recombination of GAL4-BD Gateway
destination vectors with sequence verified Gateway entry vectors containing the
cDNA’s of selected bait proteins.
Constructs encoding full-length or fragments of bait proteins fused to a DNA-
binding domain (GAL4-BD) were used as baits to screen human oligo-dT primed
retinal, brain, kidney and testis cDNA libraries, a bovine random primed retinal
cDNA library66 or a library of human cDNA’s from candidate and known ciliary
proteins, fused to a GAL4 activation domain (GAL4-AD) or vice versa67. The yeast
strain PJ96-4A, which carries the HIS3 (histidine), ADE2 (adenine), MEL1
(a-galactosidase) and LacZ (b-galactosidase) reporter genes, was used as a host.
Interactions were analysed by assessment of reporter gene activation based on
growth on selective media (HIS3 and ADE2 reporter genes), a-galactosidase
colorimetric plate assays (MEL1 reporter gene), and b-galactosidase colorimetric
filter lift assays (LacZ reporter gene).
Ciliopathy genetic variants from UK10K data. We downloaded ciliopathy
patient data from the European genome-phenome archive (EGA), which consists
of variants sequenced from 124 ciliopathy disease samples in 12 disease groups and
1 control. We mapped genomic variants using the Ensembl Variant Effect Pre-
dictor68. For each allele, we took the maximum allele frequency from those given
by 1,000 Genomes69 and Exome Aggregation Consortium (exac.broadinstitute.org)
and in all instances only considered those lower than 1%. We computed the ratio
between the frequency of variants in the UK10K and the 1,000 genome project,
correcting these for the overall mutation rates in each set (to account for platform/
variant calling differences). We calculated a P value using a binomial test for each
particular type of variation, compared (disease versus background) by Fischer’s
method. We considered genes having a ratio Z2 and a P value r0.01 as those
significantly mutated in ciliopathies (either pooled or separately) relative to the
healthy population (that is, in Figs 1 and 2). For Supplementary Data 5 we
considered only homozygous/heterozygous (labelled) missense mutations with
frequencies below 1%.
Immunohistochemistry. Unfixed kidneys and brains of 1-month-old Wistar rats
were harvested and frozen in melting isopentane. Seven micrometre cryosections
were cut and treated with 0.01% Tween in PBS for 20min and subsequently
blocked in blocking buffer (0.1% ovalbumin and 0.5% fish gelatin in PBS). After the
blocking step, the cryosections were incubated overnight with the primary rabbit
polyclonal antibody targeting GID8 (c20orf11 (N1C3), Genetex, cat. no.
GTX106672; 1:100) or MKLN1 (Sigma-Aldrich, cat. no. HPA022817; 1:100) in
combination with the monoclonal antibody GT335 (Adipogen, cat. no. AG-20B-
0020-C100; 1:1,000), diluted in blocking buffer. Alexa Fluor 488- and 568-con-
jugated secondary antibodies were also diluted 1:500 in blocking buffer and
incubated for 1 h in the dark. Staining of cell nuclei was performed with DAPI
(1:8,000). Prolong Gold Anti-fade (Molecular Probes) was used for embedding the
sections. Pictures were made with a Zeiss Axio Imager Z1 fluorescence microscope
(Zeiss), equipped with a 63 objective lens and an ApoTome slider. Images were
processed using Axiovision 4.3 (Zeiss) and Adobe CS4 Photoshop (Adobe Sys-
tems). Procedures followed were in accordance with the ethical standards of the
responsible committee on animal experimentation.
Ciliary staining of HEK293T cells. HEK293T cells were cultured in DMEM
(PAA) supplemented with 10% fetal bovine serum and 0.5% penicillin/strepto-
mycin. HEK293T cells were plated on glass slides coated with 0.01% poly-L-lysine
(P8920 SIGMA) as described in the manufacturer’s protocol. Slides were sub-
merged in poly-L-lysine for half an hour and then rinsed twice with sterile MilliQ
and allowed to dry for 1 h in the hood prior to use. Twenty-four hours after plating
cells were starved for 48 h in 0.1% FCS (50% starvation medium and 50% 1 PBS),
0.2% starvation medium, or full (10% FCS) medium. All conditions showed ciliated
cells. IF images illustrate cells from the 0.1% starvation conditions. Cells were
rinsed once with 1 PBS at room temperature and then fixed in 2% PFA for
20min and permeabilized with 1% Triton-X for 5min. Cells were blocked in
freshly prepared 2% BSA for 40min and then incubated with the following anti-
bodies for 1 h: a rabbit anti-ARL13B antibody (Proteintech, cat. no. 17711-1-AP;
1:500), a guinea pig polyclonal anti-RPGRIP1L antibody (SNC040, 1:300), and a
monoclonal anti-acetylated tubulin antibody (clone 6-11-B1, Sigma-Aldrich,
T6793; 1:1,000). Cells were stained with secondary antibodies for 45min. The
following secondary antibodies were used (all from Life Technologies/Thermo
Fisher Scientific, Bleiswijk, The Netherlands; all diluted 1:500 in 2% BSA): anti-
guinea pig IgG Alexa Fluor 647, anti-rabbit IgG Alexa Fluor 488, and anti-mouse
IgG Alexa Fluor 568. DAPI stained the nucleus.
TMEM41B ciliary phenotype. Cell line used. Human kidney-2 (HK2) cells were
cultured in DMEM F-12 5% FBS and supplied with ITS (SIGMA, I1884), 100 units
per ml penicillin, and 100 mgml 1 streptomycin. Starvation in HK2 cells was
achieved using DMEM F-12 without FBS for 24 h. Cells were grown at 37 C with
5% CO2.
Immunofluorescence. Cells were fixed in 4% paraformaldehyde. Blocking was
performed in PBS-0.2% Triton X-100, 10% FBS. For cilia staining cells were starved
for 24 h before fixation. Cilia were labelled with a rabbit anti-ARL13B antibody
(Proteintech, cat. no. 17711-1-AP). Anti-FLAG was from Sigma (A8592). A total of
300 cells for mock, 150 cells for Clone A, 400 cells for Clone B were counted in the
overexpression experiments. For siRNA interference experiments 70 cilia were
measured for the negative control and 72 cilia were measured for TMEM41B
depleted cells. Cilia length was measured using ImageJ (NIH). Cell confluence was
comparable between overexpressing and control cells. The P value was calculated
with the t-Test **P valueo0.01; ***P valueo0.0001.
Transfections. TMEM41B was cloned in a p3XFLAG-CMVTM-14 expression
vector (from Sigma-Aldrich E7908). HK2 cells were transfected using TransIT-LT1
Transfection Reagent (Mirus) according to the manufacturer’s instructions and
cells were collected 72 h after transfection both for WB and IF. As control, cells
were treated with the Transfection reagent alone (Mock).
RNAi. ON-TARGET plus smart pool siRNAs against human TMEM41B and
non-targeting control pool from Dharmacon were used at a concentration of
100 mM. The transfection reagent was INTERFERIN (409-10 from Polyplus).
Silenced cells were used for IF analyses 96 h after transfections.
3M syndrome proteins and relationship to cilia function. Cell culture. Murine
principle collecting duct (mpkCCD) clone 11 cells were grown with DMEM/Ham
F12 1:1 vol/vol supplemented with 5 mgml 1 insulin; 50 nM dexamethasone;
60 nM sodium selenate; 5 mgml 1 transferrin; 1 nM triiodothyronine (T3);
2mM glutamine; 10mgml 1 epidermal growth factor (EGF); 2% fetal calf serum
(FCS); 10% D-glucose; 20mM HEPES, pH 7.4 and 10 mgml 1 ciproxin at 5%
CO2.Human fibroblasts were grown from skin biopsies in DMEM supplemented
with 10% FCS and 1% P/S. Cells were incubated at 37 C in 5% CO2 to B90%
confluence. Fibroblasts were serum starved for 48 h before fixation.
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Antibodies and reagents. Antibodies used are mouse anti-CUL7 (clone Ab38,
Sigma-Aldrich, C1743, diluted 1:500), mouse anti-acetylated tubulin (clone
6-11-B1, Sigma-Aldrich, T6793, diluted 1:20,000), rabbit anti-MKS1 (Proteintech
16206-1-AP, at 1:300) and rabbit anti-p38 MAPK Antibody (Cell Signaling, #9212,
at 1:1,000).
Plasmid DNA transfection (1 microgram per well in a 6-well plate) was
performed with Lipofectamine2000 (Thermo Fisher Scientific, 11668-019),
according to the supplier’s protocol. Opti-MEM (Thermo Fisher Scientific,
31985-062) was used to dilute the plasmids or mutant alleles. Human Wild-type
plasmids were a kind gift from Dr Dan Hanson at University of Manchester,
UK as previously published70: Myc-tagged CUL7, V5-tagged-OBSL1 and CCDC8.
Lipofectamine RNAimax (Thermo Fisher Scientific, 13778-075) was used for
siRNA transfection of pooled siRNAs at a total final concentration of 20 nM,
according to the supplier’s protocol. Opti-MEM (Thermo Fisher Scientific,
31985-062) was used to dilute the ON-TARGETplus siRNA SMARTpools
(Dharmacon): Non-targeting pool siCtrl (D-001810-10), mouse Ift88
(L-050417-00), mouse Obsl1 (L-058142-01), mouse Cul7 (L-054741-01),
mouse Ccdc8 (L-067567-00).
RT-qPCR. RNA was isolated from cells using RNeasy Mini kit (Qiagen)
an reverse transcription was performed using Siperscript III (Thermo Fisher
Scientific). Quantitative real-time PCR was carried out using Sybr Green (Qiagen)
and run in a MyiQ Single-color real-time PCR detection system (Bio-as
Laboratories). Data were normalized to Gapdh. The mouse primer sequences
(Sigma) used and concomitant annealing temperatures can be provided upon
request. The DDCT method was used for statistical analysis to determine gene
expression levels.
Western blot. Protein lysates were prepared using RIPA lysis buffer. To correct
for protein content BCA protein assay (Pierce) was performed. Anti-MAPK
(1:1,000) was used as loading control in combination with Coomassie Blue staining.
After SDS–PAGE separation and transfer, the PVDF membranes were blocked in
5% dried skim milk in TBS with 0.5% Tween. The primary antibody (or anti-CUL7
at 1:500) was incubated overnight at 4 C. The secondary swine anti-rabbit and
rabbit anti-mouse antibodies which are HRP conjugated (DAKO, dilution 1:2,000)
were incubated for 1 h at RT. The ECL Chemiluminescent Peroxidase Substrate kit
(Sigma, CPS1120-1KT) was used for development. Scans of the blots were made
with the BioRad ChemiDoc XRSþ device with Image Lab software 4.0.
Immunofluorescence. For immunostaining, mpkccd cells or fibroblasts were
grown on glass coverslips and fixed for 5min in ice-cold methanol and blocked
60min in 1% BSA. Primary antibody incubations (mouse anti-acetylated tubulin
1:20,000, rabbit anti-MKS1, 1:300) were performed at 4 C overnight in 1% BSA.
Goat anti-mouse 488/-rabbit 568 Alexa secondary antibody (Thermo Fisher
Scientific, dilution 1:500) and DAPI incubations were performed for 2 h at RT.
Coverslips were mounted in Fluormount G (Cell Lab, Beckman Coulter). Confocal
imaging was performed using Zeiss LSM700 confocal laser microscope and images
were processed with the ZEN 2012 software.
Statistics. P values were calculated of normally distributed data sets using a
two-tailed Student’s t-test, or one-way ANOVA with Dunnett’s post hoc test,
or two-way ANOVA with Bonferroni post hoc tests. Statistical analyses represent
the mean of at least three independent experiments; error bars represent s.e.m. or
indicated otherwise.
Data availability. Interaction, and complex data are available and http://landscape.
syscilia.org/. Additionally, the protein interactions from this publication have been
submitted to the IMEx (http://www.imexconsortium.org) consortium through IntAct
(http://www.ebi.ac.uk/intact/) and assigned the identifier IM-25054.
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